Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

e-pub ahead of print date: 20 April 2023

Published date: 1 July 2023

Additional Information: Funding Information: The study is funded by the UK Government through the National Institute for Health Research ( NIHR ) and the Vaccine Taskforce ( VTF ). The award ID is NIHR203292 . The study Sponsor is University Hospital Southampton NHS Foundation Trust , Southampton, UK. ChAd, BNT and m1273 used in this study were supplied by the UK Health Security Agency (previously Public Health England). NVX, VLA, Ad26 and CVn were supplied by the manufacturers, without charge. The research is supported by the NIHR Southampton Clinical Research Facility and Biomedical Research Centre , the NIHR Clinical Research Facilities and NIHR Clinical Research Network and the NIHR-funded National Immunisation Schedule Evaluation Consortium ( NISEC , NIHR PR-R17-0916-12001 ). SNF and MDS are NIHR Senior Investigators. KC is a Wellcome Trust Investigator (210755/Z/18/Z) and NIHR Senior Investigator Emeritus. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The investigators would like to thank the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Heath Research Authority (HRA) for their extraordinary efforts in rapidly reviewing submissions, for their attention to detail and input into trial design. Specific thanks go to Drs Kirsty Wydenbach, Lisa Campbell, David Jones, Graham McNaughton, Marie-Christine Bielsky and David Brown at the MHRA; to Drs David Carpenter (Chair) and Mike Proven (Vice-Chair) and all volunteer officers/members of the South Central, Berkshire Research Ethics Committee; and to Kevin Ahmed and all HRA staff who supported the trial. The investigators express their gratitude for the contribution of all trial participants, the UK Vaccine TaskForce (Jacinda Kemps, Kate Taylor, Kate Hilyard) and the invaluable advice of the trial committees. Professors Andrew Ustianowski (Chair) and Chris Rogers, and Dr Andrew Riordan serve as the independent members of the Data Monitoring and Safety Committee and Professor Robert Read is the Chair of the Trial Steering Committee. Funding Information: The study is funded by the UK Government through the National Institute for Health Research (NIHR) and the Vaccine Taskforce (VTF). The award ID is NIHR203292. The study Sponsor is University Hospital Southampton NHS Foundation Trust, Southampton, UK. ChAd, BNT and m1273 used in this study were supplied by the UK Health Security Agency (previously Public Health England). NVX, VLA, Ad26 and CVn were supplied by the manufacturers, without charge. The research is supported by the NIHR Southampton Clinical Research Facility and Biomedical Research Centre, the NIHR Clinical Research Facilities and NIHR Clinical Research Network and the NIHR-funded National Immunisation Schedule Evaluation Consortium (NISEC, NIHR PR-R17-0916-12001). SNF and MDS are NIHR Senior Investigators. KC is a Wellcome Trust Investigator (210755/Z/18/Z) and NIHR Senior Investigator Emeritus. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The investigators would like to thank the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Heath Research Authority (HRA) for their extraordinary efforts in rapidly reviewing submissions, for their attention to detail and input into trial design. Specific thanks go to Drs Kirsty Wydenbach, Lisa Campbell, David Jones, Graham McNaughton, Marie-Christine Bielsky and David Brown at the MHRA; to Drs David Carpenter (Chair) and Mike Proven (Vice-Chair) and all volunteer officers/members of the South Central, Berkshire Research Ethics Committee; and to Kevin Ahmed and all HRA staff who supported the trial. The investigators express their gratitude for the contribution of all trial participants, the UK Vaccine TaskForce (Jacinda Kemps, Kate Taylor, Kate Hilyard) and the invaluable advice of the trial committees. Professors Andrew Ustianowski (Chair) and Chris Rogers, and Dr Andrew Riordan serve as the independent members of the Data Monitoring and Safety Committee and Professor Robert Read is the Chair of the Trial Steering Committee. Publisher Copyright: © 2023 The Authors

Keywords: Antibodies, Boosters, COVID-19, Immunisation, Immunogenicity, SARS-CoV-2, T-Cells, Vaccination

Local EPrints ID: 476989

URI: http://eprints.soton.ac.uk/id/eprint/476989

DOI: doi:10.1016/j.jinf.2023.04.012

ISSN: 0163-4453

PURE UUID: 6d9d28a9-dbf0-4d4b-be15-f114a14b904d

ORCID for Christine E. Jones: orcid.org/0000-0003-1523-2368

ORCID for Robert C. Read: orcid.org/0000-0002-4297-6728

ORCID for Saul N. Faust: orcid.org/0000-0003-3410-7642

Date deposited: 23 May 2023 16:33

Last modified: 17 Mar 2024 03:45